Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

A study investigating GSK’s investigational herpes simplex virus (HSV) vaccine candidate failed to meet its primary efficacy endpoint.

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr. Tomoko Maeda-Chubachi, M.D., Ph.D., as our Chief ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

A vaccine for the prevention of shingles in adults aged 50 and over and those aged 18 and over at increased risk KUALA LUMPUR ...

GlaxoSmithKline Pharmaceuticals Ltd. engages ... medicines range across therapeutic areas such as anti-infective, dermatology, gynecology, diabetes, cardiovascular disease and respiratory diseases.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

GSK-3739937 is commercialized by GSK, with a leading Phase I program in Human Immunodeficiency Virus (HIV) Infections (AIDS).

This summary of recent health news includes U.S. Senator Bernie Sanders advocating for cheaper Ozempic, new findings on ...